CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 157 filers reported holding CLOVIS ONCOLOGY INC in Q1 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $518 | – | 16,795 | +6618.0% | 0.08% | – |
| Q4 2022 | $0 | – | 250 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 250 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 250 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 250 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | +100.0% | 250 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | -50.0% | 250 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | -33.3% | 250 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $3,000 | +200.0% | 250 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | -75.0% | 250 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $4,000 | -42.9% | 250 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $7,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |